Androfeme, a testosterone cream developed in WA, offers a groundbreaking treatment for hypo-active sexual desire dysfunction, a common menopause side effect, but is not covered by the Pharmaceutical Benefits Scheme, costing $100 for a 100-day supply compared to $31.60 for men’s equivalents. Doctors advocate for its inclusion in the PBS to improve accessibility, as ongoing trials explore its effectiveness on additional menopause symptoms.
